Ching-Liang Ho

1.5k total citations
27 papers, 923 citations indexed

About

Ching-Liang Ho is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ching-Liang Ho has authored 27 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ching-Liang Ho's work include Eosinophilic Disorders and Syndromes (4 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Ching-Liang Ho is often cited by papers focused on Eosinophilic Disorders and Syndromes (4 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Ching-Liang Ho collaborates with scholars based in Taiwan, United States and Egypt. Ching-Liang Ho's co-authors include Terra L. Lasho, Ayalew Tefferi, Tsu-Yi Chao, Te‐Chun Hsia, Gordon W. Dewald, Chong‐Jen Yu, Gee‐Chen Chang, Pan‐Chyr Yang, Lecia V. Sequist and Sai‐Hong Ignatius Ou and has published in prestigious journals such as Blood, PLoS ONE and The Lancet Oncology.

In The Last Decade

Ching-Liang Ho

27 papers receiving 907 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ching-Liang Ho Taiwan 13 475 451 251 221 140 27 923
Zhiwei Chen China 19 346 0.7× 353 0.8× 301 1.2× 139 0.6× 103 0.7× 46 965
Donnah Jones United States 12 280 0.6× 221 0.5× 166 0.7× 61 0.3× 177 1.3× 14 740
Satoshi Okazaki Japan 17 391 0.8× 153 0.3× 169 0.7× 42 0.2× 104 0.7× 86 725
Yu‐Nien Sun United States 13 206 0.4× 129 0.3× 298 1.2× 155 0.7× 92 0.7× 30 702
Cecilie L. Bager Denmark 16 267 0.6× 120 0.3× 270 1.1× 81 0.4× 118 0.8× 35 937
David Berz United States 16 269 0.6× 216 0.5× 382 1.5× 29 0.1× 147 1.1× 75 932
Massimo Zeuli Italy 14 546 1.1× 276 0.6× 226 0.9× 101 0.5× 90 0.6× 37 917
Tao Ji United States 10 637 1.3× 400 0.9× 489 1.9× 108 0.5× 107 0.8× 28 1.5k
Sheng Yang China 16 406 0.9× 196 0.4× 149 0.6× 31 0.1× 192 1.4× 105 781

Countries citing papers authored by Ching-Liang Ho

Since Specialization
Citations

This map shows the geographic impact of Ching-Liang Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching-Liang Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching-Liang Ho more than expected).

Fields of papers citing papers by Ching-Liang Ho

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ching-Liang Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching-Liang Ho. The network helps show where Ching-Liang Ho may publish in the future.

Co-authorship network of co-authors of Ching-Liang Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Ching-Liang Ho. A scholar is included among the top collaborators of Ching-Liang Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ching-Liang Ho. Ching-Liang Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shan, Yan‐Shen, Chin‐Fu Hsiao, Tsang-Wu Liu, et al.. (2021). High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial. Radiotherapy and Oncology. 158. 146–154. 8 indexed citations
2.
3.
4.
5.
Wu, Yi‐Ying, Yi-Ting Hwang, Wann-Cherng Perng, et al.. (2016). CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer. Journal of the Formosan Medical Association. 116(2). 114–122. 16 indexed citations
6.
Chang, Feng‐Yee, Tsu-Yi Chao, Woei-Yau Kao, et al.. (2016). Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence. Journal of Microbiology Immunology and Infection. 51(1). 123–131. 25 indexed citations
7.
Wu, Yi‐Ying, et al.. (2015). A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer. Oncology Letters. 10(3). 1793–1798. 1 indexed citations
8.
9.
Chen, Jia‐Hong, Yi‐Ying Wu, Ming–Shen Dai, et al.. (2014). The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation—a single institutional experience in Taiwan. Annals of Hematology. 94(1). 107–115. 7 indexed citations
10.
Li, Pengfei, et al.. (2013). Pulmonary pleomorphic carcinoma with multiple metastases to the right posterior knee complicated by paraneoplastic hypercalcemia. Oncology Letters. 7(2). 452–454. 2 indexed citations
11.
Huang, Tzu‐Chuan, Ping‐Ying Chang, Ming–Shen Dai, et al.. (2013). Malignant bowel obstruction: A retrospective clinical analysis. Molecular and Clinical Oncology. 2(1). 13–18. 7 indexed citations
12.
13.
Ho, Ching-Liang, et al.. (2012). Rapid identification of heterozygous or homozygous JAK2V617F mutations in myeloproliferative neoplasms using melting curve analysis. Journal of the Formosan Medical Association. 111(1). 34–40. 4 indexed citations
14.
Yang, James Chih‐Hsin, Jin‐Yuan Shih, Wu‐Chou Su, et al.. (2012). Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. The Lancet Oncology. 13(5). 539–548. 332 indexed citations
15.
Wu, Yi‐Ying, et al.. (2010). Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clinica Chimica Acta. 412(1-2). 181–185. 32 indexed citations
16.
Chen, Wei‐Liang, Wen‐Chiuan Tsai, Tsu-Yi Chao, et al.. (2009). The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Annals of Hematology. 89(6). 553–562. 40 indexed citations
17.
Ho, Ching-Liang, et al.. (2008). Clinical Correlates of Serum Pro-Major Basic Protein in a Spectrum of Eosinophilic Disorders and Myelofibrosis. Acta Haematologica. 120(3). 158–164. 1 indexed citations
18.
Ho, Ching-Liang, Terra L. Lasho, Joseph H. Butterfield, & Ayalew Tefferi. (2007). Global cytokine analysis in myeloproliferative disorders. Leukemia Research. 31(10). 1389–1392. 25 indexed citations
19.
Ho, Ching-Liang, et al.. (2005). Non-Hodgkin's Lymphoma of the Stomach: Treatment Outcomes for 57 Patients Over a 20-Year Period. Journal of the Chinese Medical Association. 68(1). 11–15. 6 indexed citations
20.
Chao, Tsu-Yi, et al.. (2004). Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. Journal of Biomedical Science. 11(4). 511–516. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhiwei Chen Breakdown of academic impact, for papers by Donnah Jones Breakdown of academic impact, for papers by Satoshi Okazaki Breakdown of academic impact, for papers by Yu‐Nien Sun Breakdown of academic impact, for papers by Cecilie L. Bager Breakdown of academic impact, for papers by David Berz Breakdown of academic impact, for papers by Massimo Zeuli Breakdown of academic impact, for papers by Tao Ji Breakdown of academic impact, for papers by Sheng Yang
Rankless by CCL
2026